Chicago, ILNCT05229432Now EnrollingIRB Ready

Eosinophilic Gastritis Clinical Trial in Chicago, IL

Access cutting-edge eosinophilic gastritis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Children's Hospital Medical Center, Cincinnati

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access eosinophilic gastritis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related eosinophilic gastritis treatment provided free

Apply for This Chicago Location

Check if you qualify for this eosinophilic gastritis clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Eosinophilic Gastritis Study in Chicago

Purpose: The study is a cross-sectional observational study designed to determine if eosinophilic gastritis (EG) results in gastric motility impairment. Hypothesis: Gastric dysfunction occurs in the natural history of EG but is underdiagnosed due, in part, to contraindications to the use of the standard meals used in gastric emptying studies.

Sponsor: Children's Hospital Medical Center, Cincinnati

Who Can Participate

Inclusion Criteria

Eosinophilic gastritis (EG) defined as at least one endoscopy with histopathologic evidence of ≥ 30 eosinophils in 5 or more high powered fields (hpf's) with associated symptoms of EG.
Patient reported symptoms starting at least one year or more prior to screening consistent with a diagnosis of EG: nausea, vomiting, early satiety, abdominal pain/bloating, regurgitation, diarrhea.
Symptoms suggestive of a possible gastric motility disorder during the 60 days prior to screening including: nausea, vomiting, early satiety, post-prandial feeling of fullness or bloating.
Tolerance and willingness to consume the oatmeal meal in this study.

Exclusion Criteria

Diagnosis of eosinophilic enteritis.
Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).
Known disorders associated with eosinophilic gastrointestinal (GI) diseases (e.g., D 816 V Kit+ systemic mastocytosis, Marfan syndrome or Loey's Dietz Syndrome).
Known inflammatory or autoimmune disorders associated with gastric dysmotility such as systemic sclerosis, lupus or eosinophilic fasciitis.
Uncontrolled diabetes or known diabetic complications of gastroparesis, neuropathy or nephropathy.
Taking opioid agents in the 2 weeks prior to screening and throughout the study.
History of strictures in the small bowel or stomach (e.g., pyloric stenosis) or gastric surgeries or procedures such as pyloromyotomy, pyloric dilation, pyloric resection, vagotomy, bariatric surgery or post-Nissen fundoplication or antrectomy with Billroth I, Billroth II or Roux-en-Y gastrojejunostomy.
Past or current medical problems or findings such as: advanced liver disease (Child's B or C), acute or chronic renal disease (serum creatinine \> 3 mg/dL), neurologic disease (e.g., dysautonomia), achalasia and adrenal insufficiency.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT05229432) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Eosinophilic Gastritis Treatment Options in Chicago, IL

If you're searching for eosinophilic gastritis treatment options in Chicago, IL, this clinical trial (NCT05229432) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced eosinophilic gastritis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all eosinophilic gastritis clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Chicago, IL

See all ankylosing spondylitis clinical trials recruiting in Chicago — not just this study.

Browse Ankylosing Spondylitis Trials in Chicago →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL